PBM audits in 2025 reject pharmacies for minor documentation variances that were previously accepted, with recoupment demands arriving years after prescriptions were filled

PBMs conduct audits of pharmacy claims and demand recoupment for any discrepancy found. In 2025, these audits became dramatically more aggressive. According to pharmacy law firm Buchanan Ingersoll & Rooney, PBMs increased the number of audits conducted, expanded the scope of what they examine, and began enforcing technical documentation standards with unprecedented rigidity. Documentation that was historically accepted -- minor variances in quantity notation, timestamps, or refill authorization formats -- is now being rejected. PBMs have also begun citing audit findings from one or two years ago as evidence of a broader pattern of non-compliance, using old findings to justify new recoupment demands. For an independent pharmacy filling 200-300 prescriptions per day, even a 1-2% discrepancy rate can generate five-figure recoupment demands. The pharmacy cannot effectively dispute findings because PBM contracts give the PBM unilateral authority to determine what constitutes a discrepancy. State pharmacy fair audit laws were supposed to protect pharmacies: they limit how far back PBMs can review claims, prohibit extrapolation (using a sample of claims to calculate recoupment across all claims), and require PBMs to provide detailed findings before demanding payment. But pharmacies regularly report that PBMs conduct extrapolation audits despite clear state prohibitions, and enforcement of these laws is essentially nonexistent. A pharmacy that refuses to pay a recoupment demand risks being terminated from the PBM network, which would cut off access to the majority of its patients' insurance plans -- a business death sentence. The structural problem is that PBM audits are not primarily about compliance -- they are a profit center. The PBM has already been paid by the health plan for the prescription. When it claws back payment from the pharmacy, the PBM keeps the difference. There is no requirement for the PBM to return recouped funds to the health plan or the patient. This creates a perverse incentive: the more aggressively the PBM audits, and the more technical the standards it enforces, the more money it extracts from pharmacies. The pharmacy's only recourse is expensive litigation, which most independent owners cannot afford. PBMs know this, and they calibrate their recoupment demands accordingly -- large enough to be profitable, small enough that litigation costs more than paying.